Stryker shows mixed analyst sentiment, shares hold firm in the S&P 500
23.06.2026 - 19:13:29 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 19:12.
Stryker Corp. (US8636671013) draws a split analyst picture this week. The S&P 500 medtech group trades on the NYSE around 308 US dollars, while two recent research notes from Barclays and Bank of America trim price targets and highlight a more cautious view on sector growth.
What recent notes say
Barclays lowered its price target for Stryker in late May, describing the company’s first-quarter results as “mixed” and signaling a more reserved stance on valuation, according to a Barclays update summarized by Yahoo Finance. Bank of America followed on 22 June with its own price target cut, raising the question whether a broader medtech slowdown is starting to show in order trends and hospital capital spending.
Despite the cuts, both houses keep Stryker in positive territory on their rating scales, focusing on the company’s strong positioning in orthopedics and surgical technologies. Consensus data compiled by several platforms still shows an overall “Buy” stance with an average target in the high 380-dollar range, implying double-digit upside from current levels.
How consensus lines up
On TradingKey, Stryker shares recently changed hands at about 308.57 US dollars, giving the company a market capitalization above 116 billion dollars and a trailing price-earnings ratio around 35. The same data set cites an aggregate analyst price target close to 387 dollars and an overall “Buy” recommendation, putting Stryker among the higher-rated names in US medical technology.
FinancialData shows a similar picture, with Stryker quoted at 308.36 dollars as of 2026-06-23 10:44:53, up roughly 1.2 percent on the day, and classifies the group squarely in the health care equipment segment. On the German platform Finanzen100, where the stock trades in Frankfurt in euro terms, Stryker is likewise grouped with medical device peers and flagged as part of the S&P 500 index.
All news and analysis on the Stryker shares
Further background, filings and intraday price data on Stryker can be found in the ad-hoc-news topic hub and on the company’s Investor Relations page.
The business behind the ticker
Stryker generates around 60 percent of its revenues from medical surgery and neurotechnology, and about 40 percent from orthopedics, according to FinancialData’s profile of the group. The portfolio includes surgical equipment, patient and caregiver safety technologies, endoscopy systems, patient handling and emergency medical equipment, and intensive care disposables.
In orthopedics, Stryker supplies implants for total joint replacements in hips, knees and shoulders as well as trauma and extremities surgeries, putting it in direct competition with peers such as Zimmer Biomet and Johnson & Johnson’s DePuy unit. New product launches in trauma and power tools remain a focus, with recent headlines highlighting the expansion of the Pangea plating system in Europe and the TPX HD power tool platform for demanding orthopedic procedures, as reported by PR Newswire and other outlets.
Where the shares trade now
The Stryker shares (US8636671013) trade on 2026-06-23, 10:44 Eastern Time on the NYSE at 308.36 US dollars according to FinancialData.
Key data on the Stryker shares
- Company: Stryker Corp.
- ISIN: US8636671013
- WKN: 864952
- Ticker: SYK
- Trading venue: NYSE
- Price (as of 2026-06-23, 10:44): 308.36 USD
- Market cap: 116.81 billion USD (as of 2026-06-23)
- Sector / industry: Health Care Equipment / Medical Devices
- Index membership: S&P 500
- Next earnings date: not officially scheduled
This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities. All data are based on sources deemed reliable but without any guarantee.
